UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2023
Commission File Number: 001-39152
FSD PHARMA INC. |
(Registrant) |
199 Bay St., Suite 4000
Toronto, Ontario M5L 1A9 Canada
(Address of Principal Executive Offices)
Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXPLANATORY NOTE
This Report on Form 6-K/A (the “Amendment”) is being furnished to correct an error in Exhibit 99.1 in the Form 6-K filed with the Securities and Exchange Commission on December 15, 2023, accession number 0001654954-015604 (the “Original Filing”). The sole purpose of this Amendment is to amend the Original Filing to correct Exhibit 99.1 to include the missing third page in Exhibit 99.1.
Except as described above, no other changes are made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing. Unless expressly stated, this Amendment does not reflect events occurring after the filing of the Original Filing, nor does it modify or update in any way the information, statements and disclosures contained in the Original Filing.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
FSD PHARMA INC. | |||
(Registrant) | |||
| |||
Date December 18, 2023 | By | /s/ Nathan Coyle |
|
Nathan Coyle |
| ||
Chief Financial Officer |
|
3 |
EXHIBIT INDEX
Exhibit |
| Description of Exhibit |
|
4 |